MyMedR

We aimed to perform meta-analyses to summarize the overall effectiveness of the mRNA-1273 vaccine against COVID-19 caused by the Delta variant from real-world studies. A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies that reported the effectiveness of the mRNA-1273 vaccine to prevent reverse transcription-polymerase chain reaction (RT-PCR) confirmed COVID-19 caused by Delta variant of SARS-CoV-2 (B.1.617.2). A random-effects meta-analysis model was used to estimate the pooled odds ratio (OR) at a 95% confidence interval (CI), and the vaccine effectiveness was indicated as (pooled OR - 1)/OR. Five studies were included for this systematic review and meta-analysis. The meta-analysis revealed that the administration of mRNA-1273 vaccine protected against RT-PCR confirmed COVID-19 caused by Delta variant ≥21 days post first dose, with pooled vaccine effectiveness of 66% (95% CI: 65%-67%), as well as ≥14 days after the second dose, with pooled vaccine effectiveness of 91% (95% CI: 84%-95%). In conclusion, the mRNA-1273 vaccine offers a substantial protection rate against RT-PCR confirmed COVID-19 caused by the Delta variant upon full vaccination, although with slightly reduced effectiveness relative to other strains of SARS-CoV-2.

The Potential Cardiovascular Benefits of COVID-19 Vaccination: Lessons from Influenza and Emerging Evidence

Kow CS, Ramachandram DS, Hasan SS

Cardiovasc Drugs Ther, 2023 Jul 08.

PMID: 37421485 DOI: 10.1007/s10557-023-07485-6

Fulltext Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19

Kow CS, Ramachandram DS, Hasan SS

Inflammopharmacology, 2023 Aug;31(4):2077-2078.

PMID: 37036557 DOI: 10.1007/s10787-023-01203-2

Fulltext Should COVID-19 be considered cardiovascular disease risk equivalent?

Kow CS, Ramachandram DS, Hasan SS

Int J Cardiol, 2023 Apr 15;377:123.

PMID: 36724830 DOI: 10.1016/j.ijcard.2023.01.076

Fulltext Hypertension and severe COVID-19

Kow CS, Ramachandram DS, Hasan SS

Hypertens Res, 2023 May;46(5):1353-1354.

PMID: 36843117 DOI: 10.1038/s41440-023-01207-z

Fulltext RAAS inhibitors in COVID-19: They are not all the same!

Kow CS, Ramachandram DS, Hasan SS

Rev Port Cardiol, 2023 Sep;42(9):815-816.

PMID: 37353197 DOI: 10.1016/j.repc.2023.04.008

Fulltext Favipiravir and hyperuricemia in patients with COVID-19-suggestions for future studies

Kow CS, Ramachandram DS, Hasan SS

Lancet Reg Health Southeast Asia, 2023 Sep;16:100267.

PMID: 37662055 DOI: 10.1016/j.lansea.2023.100267

Use of Calcium Channel Blockers and the Risk of All-cause Mortality and Severe Illness in Patients With COVID-19: A Systematic Review and Meta-analysis

Kow CS, Ramachandram DS, Hasan SS

J Cardiovasc Pharmacol, 2022 Feb 01;79(2):199-205.

PMID: 35485583 DOI: 10.1097/FJC.0000000000001144

Owing to the reported safety concerns, we aimed to perform a systematic review and meta-analysis to determine the effect of preadmission/prediagnosis use of calcium channel blockers (CCBs) on the clinical outcomes in patients with COVID-19. A systematic literature search with no language restriction was conducted in electronic databases in July 2021 to identify eligible studies. The outcomes of interest were all-cause mortality and severe illness. A random-effects model was used to estimate the pooled summary measure for outcomes of interest with the preadmission/prediagnosis use of CCBs relative to nonuse CCBs, at 95% confidence intervals (CIs). The meta-analyses revealed no significant difference in the odds of all-cause mortality [pooled odds ratio (OR) = 0.82; 95% CI 0.68-1.00; n = 58,355] and in the odds of severe illness (pooled OR = 0.83; 95% CI 0.61-1.15; n = 46,091) respectively, with preadmission/prediagnosis use of CCBs relative to nonuse of CCBs. Nevertheless, subgroup analysis of studies originated from East Asia reported a significant reduction in the odds of all-cause mortality (pooled OR = 0.50; 95% CI 0.37-0.68) and the odds of severe illness (pooled OR = 0.51; 95% CI 0.33-0.78). There may not be safety concerns with the use of CCBs in patients with COVID-19, but their potential protective effects in the East Asian patients merit further investigations.

Fulltext The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis

Kow CS, Ramachandram DS, Hasan SS

Health Sci Rep, 2023 Sep;6(9):e1549.

PMID: 37720167 DOI: 10.1002/hsr2.1549

Fulltext How to make the best of NLRP3 inhibitors in patients with COVID-19?

Kow CS, Ramachandram DS, Hasan SS

Eur J Clin Pharmacol, 2023 Aug;79(8):1143-1144.

PMID: 37294339 DOI: 10.1007/s00228-023-03518-z

Fulltext Ingestion of beta-glucans could stimulate longer-lasting cellular immunity upon administration of COVID-19 vaccines

Kow CS, Ramachandram DS, Hasan SS

J Food Biochem, 2021 Nov;45(11):e13959.

PMID: 34608650 DOI: 10.1111/jfbc.13959

Optimizing antidiabetic therapy: Enhancing COVID-19 outcomes for patients with type-2 diabetes

Kow CS, Ramachandram DS, Hasan SS

Ann Endocrinol (Paris), 2023 Dec;84(6):792.

PMID: 37903668 DOI: 10.1016/j.ando.2023.09.004

Fulltext Can Renin-Angiotensin System Inhibitors Protect Against Acute Kidney Injury in Patients With COVID-19?

Kow CS, Ramachandram DS, Hasan SS

Crit Care Med, 2022 Nov 01;50(11):e796-e797.

PMID: 36227048 DOI: 10.1097/CCM.0000000000005618

Fulltext The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Kow CS, Hasan SS, Ramachandram DS

Inflammopharmacology, 2023 Dec;31(6):3357-3362.

PMID: 37071316 DOI: 10.1007/s10787-023-01200-5

BACKGROUND AND AIMS: Vitamin C appears to be a viable treatment option for patients with COVID-19.

METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of vitamin C versus comparative interventions in patients with COVID-19. The outcome of interest was all-cause mortality.

RESULTS: The meta-analysis of eleven trials using a random-effects model revealed significant reduction in the risk of all-cause mortality with the administration of vitamin C among patients with COVID-19 relative to no vitamin C (pooled odds ratio = 0.53; 95% confidence interval 0.30-0.92). Subgroup analysis of studies that included patients with severe COVID-19 also produced findings of significant mortality reduction with the administration of vitamin C relative to no vitamin C (pooled odds ratio = 0.47; 95% confidence interval 0.26-0.84).

CONCLUSION: Overall, evidence from RCTs suggests a survival benefit for vitamin C in patients with severe COVID-19. However, we should await data from large-scale randomized trials to affirm its mortality benefits.

Displaying publications 21 - 40 of 70 in total